Overview

A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057

Status:
Completed
Trial end date:
2016-12-09
Target enrollment:
Participant gender:
Summary
This is a long-term continuation study to provide continuing treatment to subjects with SLE.
Phase:
Phase 3
Details
Lead Sponsor:
Human Genome Sciences Inc., a GSK Company
Collaborator:
GlaxoSmithKline
Treatments:
Antibodies
Belimumab